CLSD Clearside Biomedical, Inc. logo

CLSD Clearside Biomedical, Inc.

Healthcare
$0.41+0.00%ClosedMarket Cap: $2.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

-0.03

P/S

0.50

EV/EBITDA

-3.93

DCF Value

$-8.93

FCF Yield

-1318.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

85.6%

Operating Margin

-689.8%

Net Margin

-780.9%

ROE

55.5%

ROA

-223.3%

ROIC

-248.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$201.0K$-6.0M$
Q2 null$492.0K$-4.5M$
Q1 null$2.3M$-8.2M$
Q4 null$306.0K$-7.3M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy6 Hold0 Sell0 Strong Sell
NeedhamHold
2025-11-18
HC Wainwright & Co.Neutral
2025-07-18
Chardan CapitalNeutral
2025-07-18
NeedhamHold
2025-07-17

Trading Activity

Insider Trades

View All
WHITMORE BRADFORD T10 percent owner
BuyThu Aug 13
WHITMORE BRADFORD T10 percent owner
BuyThu Aug 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.79

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Peers